Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[123I]-IBVM is a radiopharmaceutical compound used primarily as a highly selective radioligand for in vivo visualization of the vesicular acetylcholine transporter (VAChT) in the brain. It is utilized with single photon emission computed tomography (SPECT) imaging to study cholinergic neuron integrity, particularly in neurodegenerative diseases such as Alzheimer's disease and dementia with Lewy bodies. By binding selectively to VAChT, [123I]-IBVM enables noninvasive quantification of cholinergic terminal density and function, providing valuable insights into disorders characterized by cholinergic deficits[1][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [123I]-IBVM.